RE:RE:RE:RE:Fighting the IBB Trendgood point. High priced pharma will be hit for optics purposes and the sales beneficiaries will be those pharma in the moderately priced range, eg CXR.
springisnear wrote: what you need to realize here is that CXR does NOT price gouge and will benefit greatly here as moneyflow from other pharma that do price gouge will come into CXR. As investors educate themselves more it will happen. CXR is completely undervalued here. A joke.